乌司他丁联合环磷腺苷葡胺治疗病毒性心肌炎的临床疗效及对相关凋亡因子的影响

doi:10.3969/j.issn.1671-7171.2022.02.034

Abstract
Figure/Table
References (13)
Related Citation (15)

Download: PDF (1140 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the clinical efficacy of ulinastatin combined with meglumine cyclic adenosine monophosphate in the treatment of viral myocarditis (VMC) and its effect on related apoptotic molecules. 【Methods】A total of 106 patients with VMC treated in our hospital were randomly divided into observation group (ulinastatin combined with meglumine cyclophosphate) and control group (meglumine cyclophosphate), with 53 cases in each group. The two groups were treated for 2 weeks. The clinical efficacy, myocardial injury indexes (cardiac troponin I (cTnI), creatine kinase (CK), creatine kinase isoenzyme (CK-MB)), the levels of apoptosis molecules (soluble apoptosis factor (sFas), soluble apoptosis related factor ligand (sFasL)) and the incidence of adverse reactions were compared between the two groups. 【Results】 Tow weeks after treatment, the total effective rate of clinical efficacy in the observation group was 92.45% (49/53), which was significantly higher than 75.47% (40/53) in the control group(χ²=5.68,P=0.017＜0.05).After 2 weeks of treatment, the levels of serum cTnI, CK, CK-MB, sFas and sFasL in the two groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 11.32% (6/53), which was higher than 5.66% (3/53) in the control group, but the difference was not statistically significant(χ²=0.49,P=0.48＞0.05).【Conclusion】 Ulinastatin combined with meglumine cyclic adenosine monophosphate is effective in the treatment of VMC patients, which can effectively reduce the myocardial injury of patients, which may be related to the inhibition of apoptotic molecules, and the addition of ulinastatin does not significantly increase the adverse drug reactions, which is worthy of clinical reference.

Key words： Virus Diseases Myocarditis Trypsin Inhibitors/PD Drug Therapy,Combination

Received: 09 August 2021

PACS:

R542.21

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Min
	XIAO Ming
	ZHOU Guo

Cite this article:

GAO Min,XIAO Ming,ZHOU Guo. Clinical Efficacy of Ulinastatin Combined with Meglumine Cyclic Adenosine Monophosphate in the Treatment of Viral Myocarditis and its Effect on Related Apoptotic Molecules[J]. JOURNAL OF CLINICAL RESEARCH, 2022, 39(2): 281-283.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2022.02.034 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2022/V39/I2/281

[1] 夏野,朱友群,刘欢年.丹参酮ⅡA磺酸钠与黄芪治疗病毒性心肌炎的临床疗效观察[J].医学临床研究,2011,28(11):1990-1991.
[2] LASRADO N,REDDY J.An overview of the immune mechanisms of viral myocarditis[J].Rev Med Virol,2020,30(6):1-14.
[3] 符武岛,曾敏,蒙绪钦,等.环磷腺苷葡胺联合莫雷西嗪治疗室性心律失常的临床研究[J].现代药物与临床,2019,34(9):2609-2612.
[4] 穆盛田,唐洁,阎东莉,等.乌司他丁通过抑制氧化应激反应改善TNF-α引起的人肺微血管内皮细胞屏障功能障碍[J].中国医科大学学报,2020,49(1):58-63.
[5] Zhou R.Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients?[J].Eur Heart J,2020,7(22):2123.
[6] 刘少云,崔松,于娜,等.瑞舒伐他汀联合环磷腺苷葡胺治疗急性心肌梗死对血清VEGF-B和GDF-15水平的影响[J].疑难病杂志,2019,18(12):1195-1199.
[7] 吕品,薜源,王付强.微RNA-21靶向调控SOX7基因影响胃癌BGC-823细胞增殖、迁移和侵袭[J].中华生物医学工程杂志,2019,25(5):565-570.
[8] 杨晶晶,廖海含,唐其柱.病毒性心肌炎心脏自噬与免疫反应相互作用研究[J].医学综述,2019,25(24):7-11.
[9] SONG F,KONG F,ZHANG H,et al.Ulinastatin Protects against CVB3-Induced Acute Viral Myocarditis through Nrf2 Activation[J].Inflammation,2018,41(3):803-810.
[10] LI C L,JIA L B,GAO J,et al.The efficacy observation of ulinastatin combined with creatine phosphate sodium in pediatric viral myocarditis[J].Eur Rev Med Pharmacol Sci,2019,23(16):7144-7151.
[11] 姚雷,杜伯祥,葛建云,等.乌司他丁对体外循环患者呼出气冷凝液IL-6、IL-8水平的影响及肺功能保护作用[J].山东医药,2020,60(8):6-10.
[12] 付晶,常莉.有机磷中毒心肌损伤患者血清凋亡促进因子及抑制因子的表达变化研究[J].中国医学创新,2019,16(3):130-133.
[13] 陈运起,郑伟民.老年冠状动脉不同病变程度患者治疗后斑块稳定性的临床分析[J].中华老年心脑血管病杂志,2020,22(11):95-97.